Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GRN | P28799 | 2/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614239 | 0.90 | KDM4E (0.51) | LMNAKDM4EMAPTAPAF1POLB | |
| SCHEMBL4754841 | 0.88 | KDM4E (0.50) | LMNAKDM4EMAPTAPAF1POLB | |
| SCHEMBL30970919 | 0.86 | GAA (0.49) | LMNAKDM4EMAPTAPAF1POLB | |
| SCHEMBL710008 | 0.85 | MAPT (0.56) | LMNAKDM4EMAPTAPAF1POLB | |
| SCHEMBL21790363 | 0.84 | LMNA (0.46) | LMNAKDM4EMAPTAPAF1POLB | |
| Hydrochloric Acid SCHEMBL8048126 | 0.84 | MAPT (0.55) | LMNAKDM4EMAPTAPAF1POLB | |
| SCHEMBL23115836 | 0.83 | KDM4E (0.51) | LMNAKDM4EMAPTAPAF1POLB | |
| SCHEMBL18718147 | 0.81 | SMN1; SMN2 (0.47) | LMNAKDM4EMAPTPOLBALDH1A1 | |
| SCHEMBL2518853 | 0.81 | HCAR3 (0.45) | LMNAKDM4EMAPTAPAF1POLB | |
| SCHEMBL29308617 | 0.81 | GRN (0.41) | KDM4EGRNSORT1HCAR3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112351778-B | Fused tricyclic heterocycles and therapeutic uses thereof | 江苏恒瑞医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| CN-112351778-A | Fused tricyclic heterocycles and therapeutic uses thereof | 江苏恒瑞医药股份有限公司 | 2021-02-09 | — | — | CN | disclosed |
| WO-2020132566-A1 | STING PYRAZOLE AGONISTS AND USES THEREOF | NIMBUS TITAN, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132566-A1 | STING PYRAZOLE AGONISTS AND USES THEREOF | NIMBUS TITAN, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-1614683-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS. INC. | 2005-06-09 | — | — | US | disclosed |
| US-6891044-B2 | Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-6884890-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | KANIA ROBERT STEVEN (US) | 2004-11-04 | — | — | US | disclosed |
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | LMNA 3648/4885KDM4E 2368/4885MAPT 812/4885 |
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | LMNA 139/4885KDM4E 3980/4885MAPT 4299/4885 |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | LMNA 4217/4885KDM4E 2480/4885MAPT 494/4885 |
| US-20050124662-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | LMNA 3648/4885KDM4E 2368/4885MAPT 812/4885 |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | LMNA 4217/4885KDM4E 2480/4885MAPT 494/4885 |
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | CDK3, BRAF, ROCK1 | LMNA 3648/4885KDM4E 2368/4885MAPT 812/4885 |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | STING1, CGAS, MAVS | LMNA 139/4885KDM4E 3980/4885MAPT 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.